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A systematic review and meta-analysis suggests that 
around 2% of scientists admit to have falsified research at 
least once (1). Up to 33% admit other questionable prac-
tices such as plagiarism, duplicate publication, undisclosed 
changes in pre-research protocols or dubious ethical be-
havior (1). There can be no doubt that discovered cases of 
research and publication misconduct represent a tip of an 
iceberg and many cases go unreported (2).
Experienced biomedical journal editors are aware of a 
“rogues’ gallery” of major fraudsters, such as Schoen, 
Hwang, Sudbo, Poehlman, Singh, and Chandra (3-8). Much 
more common are the less dramatic, because more subtle 
but probably more dangerous, examples; these are more 
dangerous because they remain undiscovered so may 
feed into meta-analyses and guidelines.
A seminar organized by the Esteve Foundation, held in 
Sitges in April 2009, concentrated on conflicts of interest 
(COI, sometimes also referred to as Competing Interests, 
CI), which underlie so much research and publication mis-
conduct.
All attendants of the meeting agreed that there were many 
sources of COI in the general process of scientific commu-
nication (Figure 1). The meeting was mainly focused on 
non-financial COI. Three introductory presentations high-
lighted some of the topics related to COI in the contempo-
rary scientific publishing enterprise.
Dr Virginia Barbour, editor of PLoS Medicine, raised the fol-
lowing issues:
– Does past or present employment with industry preju-
dice authors and researchers? 
– Journal policies on competing interests are often un-
clear or ambiguous even though the problem is common 
and consumes a disproportionate amount of editors’ time. 
– It is difficult to persuade academic institutions and indi-
vidual researchers to comply with accepted definitions of 
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Figure 1.
Main protagonists in the process of scientific communication among 
which conflict of interest may arise.
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misconduct. 
– Editors and publishers have not got to grips with non-
financial conflicts. 
– There is uncertainty and inconsistency about sanctions 
for misconduct.
Magne Nylenna, editor-in-chief of the Norwegian Electron-
ic Health Library, raised the following issues:
– Good practice vs misconduct is not a matter of black 
and white. There are shades of gray. 
– Of greatest significance is the researcher’s/author’s in-
tent – and that may be difficult to determine. 
– Extreme cases are probably unpreventable so, as in pre-
ventive medicine generally, attention to the whole popu-
lation is likely to have a better outcome than concentrat-
ing on outliers. 
- Simple guidelines are more useful than detailed, lengthy 
protocol 
– Everyone concerned merits training.
Ana Marušić, co-editor in chief of the Croatian Medical Jour-
nal, addressed the specificities of small journals:
–There are particular problems for small journals whose 
editors are likely to be academics, not full time medical 
journalists. 
– There is special risk from “scientific inbreeding” (the 
tradition of having tenure in the same institution where 
one trained). 
– In post-communist countries the concept that it is 
praiseworthy to cheat the government may be extended 
to other perceived authorities. 
– There needs to be a clear definition of when and 
how an article is retracted and what should be the 
consequences thereof.
SpECiFiC iSSuES diSCuSSEd
Generalizability
We all need to be aware of cultural differences between 
countries or even between academic disciplines in such 
matters as ethics and law, as they are applied to science. 
While science attempts to be universal and objective, issues 
which lead to research contamination, such as through 
conflicting interests, are essentially local and variable.
Whether or not it results from a conflict of interest, a 
prime example is plagiarism, which in certain cul-
tures may represent respect for one’s seniors rather than 
theft of their work.
In any case, detecting plagiarism is easier for editors of 
large and well-resourced journals that can afford to employ 
staff to use software for detection. For the overwhelming 
majority of journals plagiarism detection is based more on 
chance than on forensic detection.
In whatever manner COI presents, we need internation-
ally accepted definitions: thus, “corruption is the abuse of 
entrusted power for private gain” (9) should be axiomatic. 
There are three aspects to this definition, all culturally de-
pendent –private gain (eg, journals and reprints, citations 
in deciding promotion); power (whom are you serving?); 
and abuse, such as cultural behavior deemed improper by 
others. At the symposium, an example was given of a prin-
cipal investigator who, faced with possible misconduct by 
a researcher, sent a junior researcher to investigate with 
neither the knowledge nor the authority to be sufficiently 
critical. The choice of this researcher was, however, in line 
with local norms.
Science’s attitudes to COi
Participants considered that the scientific community is 
largely skeptical of the frequency and adverse impact of COI. 
There is a commonly held myth that science is “self-correct-
ing” and that, by default, scientists behave ethically. In addi-
tion many scientists fail to recognize that they have compet-
ing interests so, unsurprisingly, do not declare them.
Editors and publishers may be more cynical but are still less 
than properly alert to COI, especially where it is not finan-
cial. Industry connections raise suspicions but should not 
government appointments do the same? It was pointed 
out that in certain disciplines, for example toxicology, there 
is a regular flow of personnel between government regula-
tors, industry, and academia. Of course, publishers and edi-
tors might also stand to gain from having COI, in terms of 
enhancing circulation, obtaining finance for reprints or just 
improving the impact factor
Motives
The “Publish or perish” principle dominates researchers’ and 
authors’ behavior (10). Modifying this behavior will require 
widely accepted policies and adequate training and men-
toring and incentives other than just publication as an aca-
demic reward.
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The need for standards
Those journals which screen for image manipulation (eg, 
PLoS journals) tend to quantify it as about 1% of accepted 
papers. What is especially surprising is that when authors 
are asked to provide original data to further investigate po-
tential manipulation, some 25% of authors respond that 
they do not have the original data. Indeed there is no stan-
dard approach to data storage in academic institutions 
(compared to industry where there are much more strict 
standards). We need to have agreements about such mat-
ters for example how to maintain and enter record of ex-
periments and how to archive them. One difficulty is that 
the accumulation of data during a project does not follow 
the neat process of IMRAD (Introduction, Methods, Results 
and Discussion) but rather tends to be random in time.
Authorship
It is well recognized that there is poor agreement between 
editors and researchers as to the precise definitions of au-
thorship or contributorship. This leads to disputes about 
“guest” and “ghost” authors.
Reviewers
Reviewers are often unaware that they have potential COI 
outside the obvious (ie, financial) – for example, personal 
friendship (or enmity), religious beliefs or nationalism may 
get in the way. A reviewer may be over-enthusiastic or un-
necessarily hostile about a topic, without realizing he or 
she is an outlier in that respect. In small subspecialties or 
communities, finding a genuinely independent reviewer 
may be difficult.
In many journals, reviewers’ COI is not addressed. Esteve 
Fernández pointed out that in small scientific communi-
ties, which may have only 2 local journals, the reviewers 
know the authors personally and sometimes do research 
in the same topic, which is in itself COI, which has to be de-
clared and managed. In his experience, only some journals 
allow exclusion of researchers with competing interests 
from reviewing the submitted manuscript. Finally, editors 
may also have their own conflicts of interest (11).
Financial conflicts and other links with industry
In a Lancet commentary in 2000 (12), Professor David 
Weatherall from the University of Oxford discussed the 
public apology issued by the New England Journal of Medi-
cine, having discovered that in nearly half the articles on 
drug therapy published in the journal between 1997 and 
1999, authors had an undisclosed financial link to the prod-
uct manufacturer (13). Weatherall pointed out that govern-
ments worldwide were pushing universities to link up with 
industry and that “reduced support for clinical research is 
driving investigators towards industry as a source of fund-
ing.” In 2009, Marcia Angell, ex-editor of the New England 
Journal, quoted US Senator Charles Grassley, ranking Re-
publican on the Senate Finance Committee, as revealing 
that a researcher at Harvard Medical School had received 
US $1.6 million (€1.1.million) in consulting and speaking 
fees between 2000 and 2007 from pharmaceutical compa-
nies (13). These companies included those which manufac-
tured drugs which he had advocated in numerous journal 
publications. Another US academic was stated by Senator 
Grassley to control more than US$6 million (€4.2 million) 
of stock in a company he co-founded which was testing 
a drug used in psychotic depression; at the same time he 
was a principal investigator on a US National Institute of 
Mental Health grant that included research on the drug, 
about which he had co-authored three papers. Angell esti-
mated that, in the US, pharmaceutical companies pay tens 
of billions of dollars annually to physicians.
Another area of research where COI arguments have be-
come prominent is in toxicology. In an overview, Clax-
ton, from the US Environmental Protection Agency, has 
rehearsed the debate (14). For example, there has been 
criticism that health assessments of some potential car-
cinogens were carried out partly by scientists employed 
by industrial organizations which produced or distributed 
the materials in question. There is, of course, a counter-ar-
gument: namely that industrial scientists’ work is highly 
regulated, meets high standards and unfavorable results 
are not suppressed (15). The subject is complicated by the 
presence, both in research teams and in those designing 
regulation or guidelines, of scientists employed by gov-
ernment – which might itself have a vested interest in the 
data eventually published. Moreover, in many fields scien-
tists move freely between academia, industry, and govern-
ment, sometimes holding down posts funded by more 
than one institution.
Claxton (14), in a non-systematic review of toxicological 
studies where conflict of interest was discussed, acknowl-
edged cases where COI proved to have “negatively im-
pacted the designing, conducting, analysis and use of 
research efforts.” But he also uncovered evidence that 
such outside influence and collaboration “can be 
EDITORIAL10 Croat Med J. 2010; 51: 7-15
www.cmj.hr
beneficial because scientists receive additional financial 
support, there are increased opportunities for collabora-
tion and they might obtain otherwise unobtainable ma-
terials to study.”
While readers of published papers might be suspicious of 
bias resulting from COI, especially when undeclared, they 
can also be misled by the simple suppression of data or 
even of full papers. For example, Lexchin et al (15) showed 
that company-sponsored research was less likely to be 
published than that sponsored by other institutions or 
individuals. It was more likely to show a favorable result 
toward the company’s product. Company sponsored re-
search was of a generally high standard. The question is 
begged, therefore, of where are the negative studies? Fault 
may lie with sponsors, authors or editors – in that the last 
may be prejudiced against accepting “negative” studies. 
The opposite side of the coin is exemplified by the meta-
analysis of a systematic review by Tramčr et al into stud-
ies of the use of ondansetron in gastro-esophageal reflux 
disease (16): these authors found that, using the number 
needed to treat (NNT) as an outcome measure, studies 
whose data had been published more than once (that is 
duplicated or redundant publication) suggested great-
er potency than those which had not been duplicated. 
Thus, including the duplicated studies (even singly) into 
the meta-analysis reduced the NNT. One does not know 
the motivation of authors in submitting their papers more 
than once; of course, collecting citations is itself a potential 
COI in that it enhances career progression – and therefore 
likely income. But, given the “positivity” of the findings from 
these duplicate publications, it is possible that “sponsor-
ship bias” was also at work. Using the text matching search 
engine eTBLAST, Errami & Garner found 421 duplicates in 
a sample of 62 000 Medline abstracts (17): extrapolation to 
the full Medline database suggests there may be as many 
as 117 500 duplicate publications. The potential bias these 
may have introduced is clear.
More recently, a review of 1534 original oncology papers 
published in eight leading journals showed that 29% had 
conflicts of interest and 17% declared industrial funding. 
Where a COI was present, survival outcomes of studies fo-
cusing on treatment were more positive (18).
Finally, it has to be kept in mind that research is always per-
formed in the social and economical context, which very 
often determines the topic of research. This is the reason, 
for example, for more research in clinical medicine then 
in public health or health services (19).
Non-financial conflicts
These have been reviewed in an editorial by the PLoS Medi-
cine editors (20) and include such issues as political, ideo-
logical or religious beliefs, personal friendships or enmity, 
academic favoritism or jealousy and personal ambition. 
The authors quote scenarios including a reviewer whose 
religious affiliation makes her morally opposed to fetal cell 
research being asked to referee a study of a project using 
cell lines derived from an aborted fetus; and an editor send-
ing to known sympathetic reviewers a paper from an author 
who had supervised his postdoctoral fellowship and who 
remained a personal friend. Data are lacking on whether 
such non-financial conflicts prejudice the scientific record in 
a similar way to financial, industrial or governmental links.
One area of particular concern is the role of consulting 
firms employed by producers of potentially toxic chemi-
cals (including tobacco) in questioning studies that have 
identified hazards (21). Such “strategic reviews” may be 
given undeserved credibility by being published in peer-
reviewed indexed journals. As Michaels states (22): “Strate-
gic data synthesis exercises, whether literature reviews or 
meta-analyses, are often little more than advocacy briefs 
made to resemble scientific papers.”
Research teams, journal editors, and publishers have their 
own unique COIs. For example, they increasingly use the 
medium of press releases to trumpet success. Partly this 
may be self-promotion but it might also represent a dis-
guised plea for funding, especially from charities (non-
profit organizations). Astute editors know that wide dis-
semination through the lay media of papers published in 
their journals can increase citations and so enhance their 
impact factor (23). In some circumstances, a COI can seem 
to be totally beneficial, for example campaigning by pa-
tient self-help groups: yet many are tied up financially with 
manufacturers of devices or drugs (24).
In the end, open disclosure provides extra information with 
which readers, consumers, and providers of grants can de-
cide on how much credence to place on the data present-
ed. While the large majority of researchers, institutions, and 
companies are honest, secrecy – whether deliberate or ac-
cidental – can breed only suspicion.
Shades of gray
From what has been stated above, it is clear that the simple 
presence of COI does not imply fraud or even any miscon-
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duct at all. COI of some sort, especially non-financial, may 
be inevitable, so not necessarily culpable. Nylenna and Si-
monsen postulated that there is no distinct line between 
ethical and unethical behavior; rather there is a continuum 
from honest error to outright fraud and what matters is in-
tention, a quality which may be impenetrable to the ob-
server (25). Nylenna has updated and amplified an illustra-
tion from that paper which is shown as the Figure 2.
COI may be part of the problem at any step in the progres-
sion shown in the Figure 2, perhaps becoming more likely 
as one proceeds steadily toward the more serious transgres-
sions. In deciding how to prevent or deal with corruption 
of the scientific record, “shades of grey” need to be borne in 
mind. Marušić pointed out at the symposium that there may 
be an additional category in post-Communist countries. Pre-
viously it was widely regarded that cheating the government 
was praiseworthy; in the post-communist era, this mindset 
may have been extended to other perceived authorities – in-
cluding employing institutions, funders, and editors.
Journal policies
When an editor informs a submitting author that he has 
concerns about a possible undeclared COI, a frequent re-
ply is that he or she did not realize that they might have 
such a problem; sometimes this may be because they have 
not read the journal’s instructions to authors or advice to 
contributors. Alternatively it may be because the journal’s 
requirements are not stated, ambiguous or incomplete. 
Thus, some journals simply require a general statement 
that the author knows of no significant competing interest. 
Others ask for specific information on funding. A minority 
demand completion of more comprehensive checklists, 
enquiring into the precise role of any supporting institu-
tion in design, analysis or preparation for publication. Cur-
rently, many of the larger journals are conducting a trial of 
a standard unified declaration available from the Interna-
tional Committee of Medical Journal Editors (ICMJE) (26) 
This declaration (available from http://www.icmje.org/coi_
disclosure.pdf ) requires all authors to complete a 4 page 
questionnaire which seeks information about any resourc-
es received by the author or his or her institution to enable 
them to complete the work; it also asks for all sources of 
revenue relevant to the submitted work received over the 
previous 3 years – not just from the entity which spon-
sored the research. Similar information is required of any 
similar financial arrangement with the spouse, partner 
or children under 18 years of all authors. They are also 
required to report any personal, professional, politi-
Figure 2.
The continuum from honest error, over misconduct to outright fraud (top horizontal axis). The vertical axis shows the continuum from non-intentional to 
intentional nature of the publication behavior, as well as from their easy to difficult detection.
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cal, institutional, religious or other associations “that a rea-
sonable reader would want to know about in relation to 
the submitted work.” Tick boxes are included specifically 
relating to gifts, grants, honoraria, payment for manuscript 
preparation, patents, royalties, payments for educational 
activities, stock options, travel and accommodation re-
imbursement, board membership, consultancy, employ-
ment, and fees for expert testimony.
It remains to be seen whether authors (and reviewers) 
comply with these stringent requirements and whether 
journal editors police them adequately. An important cri-
terion is that the corresponding author is expected to seek 
and confirm information for co-authors at the time of sub-
mission. This is important given the results of a prospective 
study on the journal disclosure form for authorship required 
by the Croatian Medical Journal. Ilakovac et al interrogated 
919 authors of 200 papers (27). The corresponding author 
of the papers completed checklists for all 919 authors and 
a blank form was subsequently sent to each individual au-
thor. The main outcome measure was test-retest differenc-
es between the corresponding authors’ self-declarations. 
Reliability of answers between the two requests was low 
to moderate both for corresponding authors themselves 
and when acting as proxies for co-authors.
Not only authors, but reviewers and editors have potential 
COI. How seriously the latter two groups take their policing 
role will be crucial. Again, the evidence is a matter for con-
cern. In a survey of 37 journals, 19/30 respondents consid-
ered it important or very important that they declare their 
editors’ COI; 13/30 gave the same answer about their editori-
al board and 11/30 those of other editorial advisers. Only half 
of those who considered the matter important had a policy 
to deal with the issue, which was “internal” and “often vague.” 
Few had mechanisms for updating declarations (28).
More recently, Wager et al received responses from 231 edi-
tors-in-chief of medical, health care, life sciences, and social 
science journals published by Wiley-Blackwell. Offered a per-
ceived severity score for their journal of 0 (not a problem) to 
3 (a very serious problem), the mean rating for undisclosed 
authorial COI was 0.73. Asked how frequently they encoun-
tered the problem (on a 0-4 scale for increasing frequency) 
the mean result was 0.90. The authors concluded that at least 
some editors of science journals may be unaware of many 
of the ethical problems that they might be facing (29).
The vast majority of biomedical journal editors are “am-
ateurs” in the sense that their editorial role is sub-
sidiary to their research or clinical employment and is of-
ten unpaid. It is hardly surprising that they are sometimes 
blind to problems that are all too evident to their “profes-
sional” colleagues from major journals. One small comfort, 
of course, is that many small specialty journals publish few 
studies, such as drug trials, where significant financial in-
terests may be at stake, so may be less prone to authorial 
misconduct.
Editors cannot claim to be without resources. Advice on 
recognizing and dealing with COI is available from the 
Web sites of ICMJE, the World Association of Medical Edi-
tors (WAME) (www.wame.org), COPE (www.publication-
ethics.org) and the Council of Science Editors (www.coun-
cilscienceeditors.org) among others. Many publishers, 
including Elsevier and Wiley-Blackwell also provide ethical 
advice for their editors. The latter’s position is described 
in detail in its Best Practice Guidelines (30) which makes 
it clear that editors, authors and peer reviewers all have a 
responsibility to disclose interests “that might appear to af-
fect their ability to present or review data objectively.” The 
guideline authors state that the existence of a COI does not 
prevent someone being listed as an author although “edi-
tors may prefer not to commission subjective articles (for 
example editorials or non-systematic reviews) from author 
with a COI” but remind editors that adapting such a policy 
runs the risk of encouraging authors to conceal relevant 
interests so may be counter-productive.
institutional responses
Systematic data are not available. However, qualitative 
data from the COPE suggests that institutions vary greatly 
in their response to allegations of misconduct by an em-
ployee, including that of undeclared COI. Frequently, edi-
tors who have been advised by COPE to request an in-
stitution to investigate a matter of concern find that the 
response is tardy or no action results. Nonetheless, many 
institutions have clearly defined and publicized policies for 
handling misconduct.
In general, research institutions or funders are responsible 
for dealing with misconduct by their employees or those 
who have contracted with them. In certain countries, re-
view and appellate functions reside in governmental bod-
ies – particularly in regard to government funded studies. 
The most developed national means of investigating mis-
conduct are in the USA, Canada, Scandinavia, Australia, and 
Germany with fledgling operations in the UK, Croatia, Chi-
na, India, and Japan (31).
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Regulatory bodies also vary in their responses: in the UK, 
the General Medical Council, with whom all practicing 
physicians must register, declares in its guidance to re-
searchers that: “You must ensure that your judgment about 
the research is not influenced, or seen by others to be in-
fluenced, by financial, personal, political or other external 
interest at any stage of the process. You should always de-
clare any conflicts that may arise to an appropriate person, 
authority or organization.” The guidance goes on to specify 
to whom researchers must declare any financial matters 
– including research ethics committees, research partici-
pants, nurses and non-clinical staff in the research team. 
The GMC can investigate complaints that a registered doc-
tor has not complied with these requirements and can 
apply sanctions, after due process of investigation, which 
might include a ban from conducting research, suspen-
sion or even erasure from the register (32).
Sanctions are also available to (and used by) the US Office 
of Research Integrity in regard to misconduct in research 
or in grant applications that have been federally funded. 
There have been calls for regulators to require authors who 
are required to submit their work for approval to share un-
derlying data collected in a study so that others can assess 
reliability; this could include agencies posting comprehen-
sive conflict disclosures on their Web sites along with sub-
mitted studies (33).
Sanctions
In general, sanctions are available only to regulatory bod-
ies, employers, and sponsors in relationship with research-
ers and authors. It can be very frustrating to editors if none 
of these are able or willing to take action. Some editors 
have proposed their own sanctions – such as banning au-
thors from submitting papers for a certain length of time or 
warning editors of related journals. But there are potential 
legal pitfalls, depending on the particular jurisdiction, of 
what might be alleged as restraint of trade or defamation. 
In consequence, COPE advises its members that, beyond 
rejecting a paper or publishing an expression of concern 
or retraction once a serious allegation has been raised or 
proved, they should go no further than asking the study 
sponsor or employing institution to investigate.
Retractions
The National Library of Medicine (NLM) states that an arti-
cle can be retracted or withdrawn by its authors, academic 
or institutional sponsor, editor or publisher, because of per-
vasive error or unsubstantiated or irreproducible data. NLM 
does not differentiate between retraction due to honest 
error and that due to misconduct. The citation for the ar-
ticle is not removed from the database but is updated to 
indicate retraction and links the original citation to the 
published retraction notice (34). Thus, there is no specific 
reference to COI, although COI may be the prime cause of 
misconduct or error.
Elsevier advises its authors that they can withdraw an ar-
ticle in press or retract one already published for various 
reasons, including infringements of professional ethical 
codes, such as multiple submission or duplication, bogus 
authorship claims, plagiarism, fraudulent data “or the like” 
but do not refer specifically to undeclared COI.
Before due process by a responsible body has made a find-
ing of misconduct but where the case appears strong, it is 
open to editors to publish a “notice of concern” or even an 
editorial explaining the issues involved – but short of any 
formal retraction.
CONCluSiONS OF THE diSCuSSiON
The existence of a COI does not necessarily imply miscon-
duct or harm but is well recognized to have the potential 
to lead to feelings of obligation or reciprocity by the in-
dividual concerned (35). Lack of transparency at the time 
of submission and publication, when followed by subse-
quent discovery of an undeclared interest, is likely to lead 
to a perception by readers and editors that the research is 
tainted, even possibly fraudulent. Neither concept is help-
ful to scientific advance or the public interest in probity.
The contrary argument is that editors habitually conflate 
serious misconduct by academics without corporate ties 
with far less heinous cases where authors have not re-
sponded appropriately to unjustifiably over-elaborate re-
quirements for disclosure (36). In an invited polemic, Stos-
sel claims that “adverse outcomes objectively ascribed to 
financial COI are almost non-existent” and that “no evi-
dence supports that corporate detailing and gifting ad-
versely affects patient care” and that COI strictures actually 
inhibit medical advances.
One way of dealing with the controversy might be to fol-
low the suggestions of Nylenna and Simonsen (25) by 
taking a population rather than an individual approach 
to COI. These authors based their argument on the 
concept proposed a quarter of a century ago by 
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Rose (37) in relation to disease prevention. Rose defined 
the prevention paradox – namely, a measure that brings 
large benefit to the community but offers little to every 
participant means that minor changes in the right direc-
tion by most of the population is more effective than ma-
jor changes by the few. The Gaussian distribution curve is 
shifted to the left. Nylenna and Simonsen conceptualize 
scientific misconduct, which would include deliberate lack 
of transparency by non-disclosure, as an unhealthy condi-
tion diffused throughout the science community to differ-
ent degrees of seriousness. By moving the whole research 
community in one direction, the number of serious cases 
can be reduced. This approach requires clear definitions 
and simple and readily available guidelines at all levels of 
research and practice, including entry, with appropriate 
mentoring and audit; national independent bodies should 
be permitted to investigate serious cases and whistleblow-
ers encouraged and safeguarded. As Marušić pointed out 
at the symposium, any such action is even more cogent in 
cultures where “scientific inbreeding” (38) has led to aca-
demics routinely enjoying tenure in the institution where 
they were trained.
dOES iT MATTER?
Editors should not underestimate readers. Many may bring 
the requisite level of skepticism in considering the validity 
or impact of published research but those who are naive 
would benefit from training in appraising scientific papers.
They should also be aware of the veneration for science 
that inhabits the popular mind. “It’s in a peer-reviewed 
journal, so it must be true” – whereas scientists know that 
all published work is merely part of work in progress, so 
may well be contradicted eventually. In this respect, re-
searchers, their institutions, and editors should understand 
how they might themselves display a COI when they in-
volve the media, for example with press releases. They may 
be demonstrating an “abuse of entrusted power.”
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